Alleviation of colonic inflammation by Lypd8 in a mouse model of inflammatory bowel disease. (5th April 2021)

• Record Type: Journal Article
• Authors: Hsu, Chiao-Ching; Okumura, Ryu; Motooka, Daisuke; Sasaki, Reo; Nakamura, Shota; Iida, Tetsuya; Takeda, Kiyoshi
• Is Part Of: International immunology. Volume 33:Number 7(2021)
• Page Start: 359
• Page End: 372
• Publication Date: 2021-04-05
• Subjects: high-fat diet -- inflammatory bowel diseases -- Lypd8 -- mucosal barrier; Immunology -- Periodicals; 616.079
• DOI: 10.1093/intimm/dxab012
• Languages: English
• ISSNs: 0953-8178

Abstract

Abstract: Dysfunction of the intestinal mucosal barrier causes inflammatory bowel diseases (IBDs). Indeed, mucosal barrier impairment in the gut of IBD patients results from decreased expression of barrier molecules. Ly6/Plaur domain containing 8 (Lypd8) segregates microbiota from the colonic epithelial layer. In this study, we found that Lypd8 − /− mice, in which flagellated bacteria invaded the mucosal surface of the colon, developed spontaneous colitis when dysbiosis was induced by a high-fat diet (HFD). On the basis of this finding, we assessed whether the application of human LYPD8 (hLYPD8) protein exhibiting the glycan-dependent inhibition of bacterial motility is effective in a colitis model. Oral and anal treatments with hLYPD8 protein ameliorate dextran sulfate sodium-induced colitis and HFD-induced colitis in Lypd8 − /− mice. These results indicate a therapeutic potential of hLYPD8 protein supplementation for IBD. Abstract : Lypd8 mediates effective protection from colitis